Literature DB >> 19407856

Intercepting early pelvic serous carcinoma by routine pathological examination of the fimbria.

Dana R Semmel1, Ann K Folkins, Michelle S Hirsch, Marisa R Nucci, Christopher P Crum.   

Abstract

Recent evidence indicates that the distal fallopian tube is the principal site of early serous cancer in women with a hereditary risk for ovarian cancer. Moreover, the fimbria is involved by early cancer in a significant minority of pelvic serous carcinomas, irrespective of whether the patient has a hereditary BRCA1 or BRCA2 mutation. In addition, the distal tube has been identified occasionally as a site of concurrent endometrioid tumors in women with endometrial carcinoma. Although the risk of sporadic fimbrial tumors in otherwise healthy women without genetic risk is unknown, routine histological examination of the fimbria provides the opportunity to determine the risk of such an event. To illustrate this point, a case of a woman who underwent surgery for an ovarian fibroma is presented. The distal tube was submitted, and found to harbor a focus of serous tubal intraepithelial carcinoma (STIC) with a 2-mm invasive tumor. Incidentally discovered carcinomas underscore the potential risk, albeit low, of concurrent unsuspected malignancy in the distal fallopian tube and emphasize the importance of routine pathological examination of the fimbria in all salpingectomies. The rationale for this strategy, and its potential effect on early detection and in uncovering persons or families potentially at risk for ovarian cancer, is discussed.

Entities:  

Mesh:

Year:  2009        PMID: 19407856      PMCID: PMC2847406          DOI: 10.1038/modpathol.2009.64

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  13 in total

1.  The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome.

Authors:  Fabiola Medeiros; Michael G Muto; Yonghee Lee; Julia A Elvin; Michael J Callahan; Colleen Feltmate; Judy E Garber; Daniel W Cramer; Christopher P Crum
Journal:  Am J Surg Pathol       Date:  2006-02       Impact factor: 6.394

2.  Recommendations for the reporting of fallopian tube neoplasms.

Authors:  Teri A Longacre; Esther Oliva; Robert A Soslow
Journal:  Hum Pathol       Date:  2007-02-01       Impact factor: 3.466

3.  Endometrioid carcinoma simultaneously involving the uterus and the fallopian tube: a clinicopathologic study of 13 cases.

Authors:  Lisa K Culton; Michael T Deavers; Elvio G Silva; Jinsong Liu; Anais Malpica
Journal:  Am J Surg Pathol       Date:  2006-07       Impact factor: 6.394

4.  Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers.

Authors:  Amy Finch; Patricia Shaw; Barry Rosen; Joan Murphy; Steven A Narod; Terence J Colgan
Journal:  Gynecol Oncol       Date:  2005-08-31       Impact factor: 5.482

5.  BRCA-mutation-associated fallopian tube carcinoma: a distinct clinical phenotype?

Authors:  Ilana Cass; Christine Holschneider; Nandini Datta; Denise Barbuto; Ann E Walts; Beth Y Karlan
Journal:  Obstet Gynecol       Date:  2005-12       Impact factor: 7.661

6.  Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction.

Authors:  Michael J Callahan; Christopher P Crum; Fabiola Medeiros; David W Kindelberger; Julia A Elvin; Judy E Garber; Colleen M Feltmate; Ross S Berkowitz; Michael G Muto
Journal:  J Clin Oncol       Date:  2007-09-01       Impact factor: 44.544

7.  Adenofibroma of the fimbria: a common entity that is indistinguishable from ovarian adenofibroma.

Authors:  Veerle Bossuyt; Fabiola Medeiros; Ronny Drapkin; Ann K Folkins; Christopher P Crum; Marisa R Nucci
Journal:  Int J Gynecol Pathol       Date:  2008-07       Impact factor: 2.762

8.  Oral contraceptive use, reproductive history, and risk of epithelial ovarian cancer in women with and without endometriosis.

Authors:  Francesmary Modugno; Roberta B Ness; Glenn O Allen; Joellen M Schildkraut; Faith G Davis; Marc T Goodman
Journal:  Am J Obstet Gynecol       Date:  2004-09       Impact factor: 8.661

9.  High risk for ovarian cancer in a prospective series is restricted to BRCA1/2 mutation carriers.

Authors:  Lovise Maehle; Jaran Apold; Torbjørn Paulsen; Bjørn Hagen; Kjell Løvslett; Bent Fiane; Marijke Van Ghelue; Neal Clark; Pål Møller
Journal:  Clin Cancer Res       Date:  2008-11-15       Impact factor: 12.531

Review 10.  Efficacy of risk-reducing salpingo-oophorectomy in women with BRCA-1 and BRCA-2 mutations.

Authors:  Olufunmilayo I Olopade; Grazia Artioli
Journal:  Breast J       Date:  2004 Jan-Feb       Impact factor: 2.431

View more
  10 in total

1.  Ovarian surface epitheliectomy in the non-human primate: continued cyclic ovarian function and limited epithelial replacement.

Authors:  Jay W Wright; Tanja Pejovic; Leigh Jurevic; Cecily V Bishop; Theodore Hobbs; Richard L Stouffer
Journal:  Hum Reprod       Date:  2011-03-18       Impact factor: 6.918

2.  Effect of tubal sterilization technique on risk of serous epithelial ovarian and primary peritoneal carcinoma.

Authors:  Collette R Lessard-Anderson; Kathryn S Handlogten; Rochelle J Molitor; Sean C Dowdy; William A Cliby; Amy L Weaver; Jennifer St Sauver; Jamie N Bakkum-Gamez
Journal:  Gynecol Oncol       Date:  2014-10-12       Impact factor: 5.482

Review 3.  The oviduct and ovarian cancer: causality, clinical implications, and "targeted prevention".

Authors:  Christopher P Crum; Frank D McKeon; Wa Xian
Journal:  Clin Obstet Gynecol       Date:  2012-03       Impact factor: 2.190

4.  Fallopian tube secretory cell expansion: a sensitive biomarker for ovarian serous carcinogenesis.

Authors:  Yiying Wang; Li Li; Yue Wang; Sarah Ngocvi Tang; Wenxin Zheng
Journal:  Am J Transl Res       Date:  2015-10-15       Impact factor: 4.060

5.  A case of non-invasive serous adenocarcinoma at unilateral fimbria with spread to the peritoneal/uterine cavity: case report.

Authors:  Yuki Fukumura; Akiko Masaoka; Toshio Naito; Miki Kimura; Takashi Yao
Journal:  Diagn Pathol       Date:  2009-12-05       Impact factor: 2.644

6.  Fallopian tube secretory cell expansion: a sensitive biomarker for ovarian serous carcinogenesis.

Authors:  Yiying Wang; Li Li; Yue Wang; Sarah Ngocvi Tang; Wenxin Zheng
Journal:  Am J Transl Res       Date:  2016-01-15       Impact factor: 4.060

7.  Early stage (IA-IB) primary carcinoma of the fallopian tube: case-control comparison to adenocarcinoma of the ovary.

Authors:  Charlotte Vaysse; Cyril Touboul; Thomas Filleron; Eliane Mery; Eva Jouve; Pierre Leguevaque; Philippe Morice; Eric Leblanc; Denis Querleu
Journal:  J Gynecol Oncol       Date:  2011-03-31       Impact factor: 4.401

8.  Induction of ovarian leiomyosarcomas in mice by conditional inactivation of Brca1 and p53.

Authors:  Bridget A Quinn; Tiffany Brake; Xiang Hua; Kimberly Baxter-Jones; Samuel Litwin; Lora Hedrick Ellenson; Denise C Connolly
Journal:  PLoS One       Date:  2009-12-31       Impact factor: 3.240

Review 9.  ARID1A mutations and PI3K/AKT pathway alterations in endometriosis and endometriosis-associated ovarian carcinomas.

Authors:  Eleftherios P Samartzis; Aurelia Noske; Konstantin J Dedes; Daniel Fink; Patrick Imesch
Journal:  Int J Mol Sci       Date:  2013-09-12       Impact factor: 5.923

10.  IMP3 signatures of fallopian tube: a risk for pelvic serous cancers.

Authors:  Yiying Wang; Yue Wang; Dake Li; Lingmin Li; Wenjing Zhang; Guang Yao; Zhong Jiang; Wenxin Zheng
Journal:  J Hematol Oncol       Date:  2014-07-12       Impact factor: 17.388

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.